<DOC>
	<DOCNO>NCT02195414</DOCNO>
	<brief_summary>The NeoVas First-in-Man study prospective , two center , single arm trial , enroll total 30 patient . The hypothesis study evaluate clinical feasibility , safety , efficacy NeoVas sirolimus-eluting bioresorbable coronary scaffold treatment patient de novo coronary lesion .</brief_summary>
	<brief_title>NeoVas Bioresorbable Coronary Scaffold First-in-Man Study</brief_title>
	<detailed_description>The primary endpoint composite endpoint cardiac death , target vessel related myocardial infarction , ischemia driven target lesion revascularization ( TLF ) 1 month follow . At 6 month , 1 , 2 , 3 , 4 5 year follow-up , clinical endpoint include TLF ( individual component ) , Patient-oriented cardiac event ( cause death , MI , revascularization ) target vessel revascularization , scaffold thrombosis .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age must 18 75 year , men unpregnant woman Patient must evidence myocardial ischemia ( e.g. , stable angina , unstable angina ) Total number target lesion =1 per patient Target lesion must ≤ 20mm length ( visual estimation ) 2.75 3.75 mm diameter（Online QCA） Target lesion visually estimate stenosis ≥ 70 % ( ≥50 % evidence myocardial ischemia ) TIMI flow ≥ 1 The target lesion cover one scaffold Patient must acceptable candidate coronary artery bypass graft . Patient able verbally confirm understand risk , benefit treatment receive NeoVas bioresorbable coronary scaffold he/she his/her legally authorize representative provide write informed consent prior clinical investigation related procedure , approve appropriate Ethics Committee respective clinical site . Patients know diagnosis acute myocardial infarction ( AMI ) within 30 day precede procedure ; CK CKMB return within normal limit time procedure Chronic total occlusion lesion ( TIMI 0 grade blood flow prior implantation ) , leave trunk vessel lesion , ostial lesion , multibranch lesion need treat , fork bridge vessel lesion branch vessel whose diameter ≥2.0mm ( branch open stenosis exceed 40 % need balloon expansion ) ; thrombus visible target blood vessel . Severe calcify lesion twisted lesion preexpanded , lesion unsuitable deliver expand stent Instent restenosis lesion Patient undergone previous stenting anywhere within target vessel ( ) within previous 12 month , require stenting within target vessel ( ) within 6 month study procedure ; target vessel plant stent year . Severe heart failure ( NYHA III grade ) , leave ventricular ejection fraction ( LVEF ) &lt; 40 % ( supersonic inspection leave ventricular radiography ) Known renal insufficiency ( e.g. , eGFR &lt; 60 ml/min , subject dialysis ) Patients hemorrhage tendency , active digestive ulcer history , cerebral hemorrhage subarachnoid hemorrhage history , cerebral apoplexy within half year , patient contraindicate platelet inhibitor anticoagulant therefore bear anticoagulation treatment Patient know hypersensitivity contraindication aspirin , clopidogrel , heparin , contrast agent , polylactic acid sirolimus adequately premedicated Life expectancy &lt; 12 month Patient participate another device drug study reach primary endpoint study . Patient 's inability fully cooperate study protocol investigator 's opinion may limit his/her ability participate study Patient heart transplant . Patient current unstable arrhythmia , high risk ventricular premature beat ventricular tachycardia . Patient receive schedule receive chemotherapy malignancy within 30 day prior procedure Patient receive immunosuppression therapy know immunosuppressive autoimmune disease Patient receiving schedule receive chronic anticoagulation therapy ( e.g. , heparin , coumadin ) Elective surgery plan within first 6 month procedure require discontinue either aspirin clopidogrel Platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 , WBC &lt; 3,000 cells/mm3 , document suspect liver disease ( include laboratory evidence hepatitis ) Patient extensive peripheral vascular disease precludes safe 6 French sheath insertion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>NeoVas</keyword>
	<keyword>Bioresorbable scaffold</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>First-in-Man</keyword>
</DOC>